HbA1c related to diabetes is one of the most important blood tests used in UK clinical practice, serving as both a diagnostic tool and a long-term measure of glucose control. Glycated haemoglobin — formed when glucose binds to haemoglobin in red blood cells — reflects average blood sugar levels over the preceding two to three months. Whether you have been newly diagnosed, are living with type 1 or type 2 diabetes, or have been told your levels are in the prediabetes range, understanding what your HbA1c result means, what can affect it, and how to manage it is essential for protecting your long-term health.

What Is HbA1c and Why It Matters in Diabetes

HbA1c reflects average blood glucose over two to three months and is used to diagnose type 2 diabetes (≥48 mmol/mol) and monitor ongoing glycaemic control, though it is not appropriate in all clinical situations.

HbA1c, or glycated haemoglobin, is a blood marker that reflects your average blood glucose levels over the preceding two to three months. When glucose circulates in the bloodstream, it binds irreversibly to haemoglobin — the protein found inside red blood cells — forming glycated haemoglobin. Because red blood cells have a lifespan of approximately 90 to 120 days, the HbA1c result provides a reliable window into longer-term glucose control, rather than a single snapshot in time.

In the context of diabetes, HbA1c is central to both diagnosis and ongoing management. According to NICE guidance (NG28), an HbA1c of 48 mmol/mol (6.5%) or above on two separate occasions is diagnostic of type 2 diabetes in adults without symptoms. For individuals with symptoms, a single result may be sufficient. A result between 42–47 mmol/mol (6.0–6.4%) indicates non-diabetic hyperglycaemia (NDH) — sometimes referred to as prediabetes — signalling an elevated risk of developing type 2 diabetes.

For people already living with diabetes, regular HbA1c monitoring helps clinicians assess how well blood glucose is being managed over time. Poor long-term control — reflected by persistently elevated HbA1c — is associated with an increased risk of serious complications, including:

• Microvascular damage: diabetic retinopathy, nephropathy, and peripheral neuropathy

• Macrovascular disease: increased risk of heart attack and stroke

Conversely, maintaining HbA1c within an individually agreed target range significantly reduces the risk of these complications.

When HbA1c should not be used for diagnosis

HbA1c is not appropriate for diagnosing diabetes in all circumstances. It should not be used as the sole diagnostic test in the following situations:

• Suspected type 1 diabetes — same-day specialist assessment is required; do not wait for HbA1c results

• Children and young people

• Pregnancy (including suspected gestational diabetes — an oral glucose tolerance test (OGTT) is used instead, per NICE NG3)

• Acute illness or symptoms of very short duration (less than two months)

• Conditions significantly affecting red blood cell turnover or haemoglobin (see the section below)

In these situations, a fasting plasma glucose or a 75 g oral glucose tolerance test (OGTT) should be used for diagnosis or confirmation, in line with NICE NG28 and WHO 2011 guidance. This is why HbA1c is considered one of the most clinically important tests in diabetes care in the UK, but must always be interpreted within the full clinical picture.

Factors That Can Affect Your HbA1c Result

Conditions altering red blood cell lifespan — including iron deficiency anaemia, haemolytic anaemia, CKD, and haemoglobin variants — can falsely raise or lower HbA1c independently of actual glucose levels.

While HbA1c is a robust and widely used marker, several physiological and clinical factors can influence the result independently of actual blood glucose levels. Understanding these variables is important for accurate interpretation, particularly when a result appears inconsistent with a patient's reported symptoms or self-monitored glucose readings.

Conditions affecting red blood cell turnover are among the most clinically significant confounders. Because HbA1c reflects glucose binding over the lifespan of red blood cells, anything that shortens or lengthens that lifespan will alter the result:

• Iron deficiency anaemia tends to raise HbA1c, because iron-deficient red blood cells have a longer lifespan, allowing more time for glycation to occur. HbA1c levels typically fall after iron repletion.

• Haemolytic anaemia (where red blood cells are destroyed prematurely) tends to lower HbA1c, as there is less time for glycation.

• Recent blood transfusion can raise or lower HbA1c depending on the glucose load of donor red blood cells and dilution effects; the direction of change is unpredictable. If transfusion has occurred recently, plasma glucose or an alternative marker (such as fructosamine or glycated albumin) should be used instead.

• Vitamin B12 or folate deficiency prolongs red blood cell lifespan and tends to raise HbA1c; levels may fall after supplementation.

• Advanced chronic kidney disease (CKD) and dialysis, as well as treatment with erythropoiesis-stimulating agents (ESAs), increase red cell turnover and tend to lower HbA1c, potentially masking poor glucose control.

• Haemoglobin variants such as HbS (sickle cell trait) or HbC can interfere with certain laboratory assays, producing unreliable results. Local laboratory or RCPath/ACB guidance should be consulted regarding assay-specific interferences.

• Splenectomy prolongs red cell lifespan and may raise HbA1c.

When HbA1c is unreliable due to any of the above, fasting plasma glucose or OGTT should be used for diagnosis, and fructosamine or glycated albumin may be considered for monitoring.

Ethnicity is a recognised factor. Research has shown that individuals of South Asian, African, or Afro-Caribbean descent may have slightly higher HbA1c values at equivalent glucose levels compared to white European populations, potentially due to differences in glycation rates or haemoglobin variants. However, UK diagnostic thresholds are not ethnicity-specific; the same 48 mmol/mol cut-off applies across all groups. NHS clinicians are advised to interpret HbA1c results in the context of the whole clinical picture, including fasting plasma glucose where results are discordant with symptoms or self-monitored glucose readings.

Pregnancy renders HbA1c unreliable for diagnosing gestational diabetes, as haemodilution and increased red cell turnover significantly affect results. Per NICE NG3, an OGTT is the recommended test for gestational diabetes. HbA1c may be used early in pregnancy to detect pre-existing (undiagnosed) diabetes, but not to diagnose gestational diabetes mellitus (GDM).

A note on other medicines: Some medications, including certain antiretroviral therapies, have been reported to affect HbA1c reliability in some individuals. If you are on complex medication regimens and your HbA1c appears inconsistent with your glucose readings, discuss this with your diabetes team, who may recommend confirmatory plasma glucose testing. If you suspect a medicine is causing an unexpected effect, you can report this via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard.

How to Lower Your HbA1c Through Lifestyle and Treatment

HbA1c can be reduced through dietary modification, at least 150 minutes of weekly aerobic activity, and pharmacological therapy; metformin is first-line, with SGLT-2 inhibitors or GLP-1 agonists added based on individual risk.

Reducing HbA1c is achievable through a combination of sustained lifestyle changes and, where necessary, pharmacological treatment. NICE guidance (NG28) emphasises that structured lifestyle intervention should be the first-line approach for people with non-diabetic hyperglycaemia and a cornerstone of management for those with established type 2 diabetes.

Dietary modification plays a particularly important role. Evidence supports the following approaches:

• Reducing intake of refined carbohydrates and added sugars, which cause rapid postprandial glucose spikes

• Adopting a low-glycaemic index (GI) diet or a Mediterranean-style diet, both of which have demonstrated reductions in HbA1c in clinical trials

• Structured very low-calorie diets (around 800 kcal/day), as used in the NHS England Type 2 Diabetes Path to Remission (Low Calorie Diet) Programme, have shown HbA1c reductions significant enough to achieve remission in some individuals. These diets are delivered under close clinical supervision and are not suitable for everyone. They are generally not appropriate during pregnancy, for those who are underweight, for people with certain eating disorders, or for those with specific comorbidities. Eligibility is assessed by your clinical team.

Physical activity independently improves insulin sensitivity and glucose uptake by skeletal muscle. NICE recommends at least 150 minutes of moderate-intensity aerobic activity per week, alongside resistance training, for adults with type 2 diabetes.

When lifestyle measures are insufficient, pharmacological therapy is initiated. Metformin remains the first-line agent for type 2 diabetes in the UK, reducing HbA1c by around 11 mmol/mol (approximately 1%) on average, though individual response varies. It works by suppressing hepatic glucose production and improving peripheral insulin sensitivity.

Second-line agents are selected based on an individual's cardiovascular, renal, and weight-related needs, in line with NICE NG28 (2022 update):

• SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin) are preferred where there is established atherosclerotic cardiovascular disease, heart failure, or CKD

• GLP-1 receptor agonists (e.g., semaglutide) are preferred where weight loss is a priority or where cardiovascular risk is high

Both classes offer additional HbA1c lowering alongside cardiovascular and renal protective benefits. If you experience any unexpected side effects from diabetes medicines, report them via the MHRA Yellow Card scheme (www.mhra.gov.uk/yellowcard or the Yellow Card app).

For people with type 1 diabetes (managed under NICE NG17), insulin regimen optimisation, carbohydrate counting, and use of real-time continuous glucose monitoring (CGM) or flash glucose monitoring — now widely available on the NHS — are key strategies for improving HbA1c without increasing hypoglycaemia risk. HbA1c targets for type 1 diabetes are individualised, typically aiming for 48 mmol/mol (6.5%) or below where this is achievable without problematic hypoglycaemia.

How HbA1c Levels Are Measured and Interpreted on the NHS

NHS HbA1c results are reported in mmol/mol; NICE recommends monitoring every three to six months when treatment is being adjusted, with targets of 48 mmol/mol for lifestyle-managed patients and 53 mmol/mol for those on hypoglycaemia-risk agents.

In the UK, HbA1c is measured using a standardised blood test, typically taken from a venous blood sample sent to an accredited laboratory. Results are reported in mmol/mol (the IFCC unit), which replaced the older percentage (NGSP/DCCT) format across NHS services following international standardisation. Some resources still display both units for clarity; as a guide, 48 mmol/mol corresponds to 6.5%, and 53 mmol/mol corresponds to 7.0%.

For most adults with type 2 diabetes managed in primary care, NICE (NG28) recommends HbA1c monitoring every three to six months when treatment is being adjusted, and every six months once stable targets are achieved. The individually agreed target will vary depending on the patient's treatment regimen, risk of hypoglycaemia, age, and comorbidities:

• 48 mmol/mol (6.5%) — target for those managed by lifestyle or metformin alone

• 53 mmol/mol (7.0%) — target for those on agents carrying a hypoglycaemia risk, such as sulphonylureas or insulin

People with non-diabetic hyperglycaemia (NDH, 42–47 mmol/mol) should usually be retested at least annually and offered referral to a structured risk-reduction programme such as the NHS Diabetes Prevention Programme (NHS DPP), in line with OHID/PHE NDH consensus recommendations.

Point-of-care HbA1c testing (using a fingerprick sample analysed in the GP surgery) is increasingly available across NHS primary care settings, offering results within minutes. However, laboratory testing remains the gold standard for diagnostic purposes. HbA1c should not be used as the sole diagnostic test in the circumstances listed in the first section of this article; fasting plasma glucose or OGTT should be used instead.

When to contact your GP or diabetes team:

• If your HbA1c is consistently above your agreed target despite adherence to treatment

• If you experience frequent hypoglycaemic episodes, which may indicate your target needs to be revised upward

• If you are pregnant or planning pregnancy, as tighter glucose control and more frequent monitoring are required

Seek urgent medical help (call 999 or go to A&E) if you develop symptoms that may suggest diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS), such as vomiting, severe abdominal pain, deep or rapid breathing, drowsiness, or signs of severe dehydration. These are medical emergencies and cannot be assessed by HbA1c alone.

Not sure if this is normal? Chat with one of our pharmacists →

Regular HbA1c monitoring, interpreted alongside self-monitored blood glucose or CGM data and clinical assessment, remains the cornerstone of safe, effective diabetes management within the NHS.

Frequently Asked Questions